It seems that the weight reduction achieved in our study is of comparable magnitude to previous trials using GLP1 receptor agonist as an anti-obesity treatment in obese subjects without diabetes, but it was achieved in a shorter period of time. The gene discussed is GLP1R; the disease is diabetes mellitus.